Cancer Conversations Podcast—Episode #16: The Latest in Prostate Cancer Treatment and Research

0
Mark Pomerantz, prostate cancer, research, Matthew Freedman, Myles Brown

Mark Pomerantz, MD (left), with Matthew Freedman, MD, and Myles Brown, MD.

Prostate cancer affects 230,000 men each year. Although diagnoses are increasing worldwide, most people die with prostate cancer and not of prostate cancer, according to Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology.

In this Cancer Conversations podcast episode, Pomerantz discusses genetics, risk factors, and the controversy surrounding the PSA test, a test that can detect levels of prostate-specific antigen in the body. Although PSA testing can help diagnose prostate cancer, it is not universally recommended in the U.S.

“If men are going to die with the disease rather than because of the disease, there are consequences to finding prostate cancer,” explains Pomerantz. “It leads to the psychological impact of having a cancer diagnosis and, more troubling, overtreatment of the disease.”

Pomerantz also discusses the promise of gene therapy, immunotherapy, and clinical trials for men with prostate cancer. “Over time, we are more and more confident that we can safely manage patients without needing immediate cure,” he says.

Listen to the podcast episode below or click “download” to listen later. Subscribe options are also available via iTunes, Google Play, the Stitcher appTuneIn app, and RSS.

The Cancer Conversations series features Q&A-style conversations with Dana-Farber physicians, clinicians, and researchers. Topics include breast cancer research, precision cancer medicine, integrative therapies, cancer genetics, and more. Visit the Cancer Conversations page for more episodes and the Dana-Farber podcast page for more cancer podcast series.

 

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dr. Matthew Davids explores combining ibrutinib with FCR (iFCR) for younger patients with previously-untreated chro… https://t.co/wzVpo47tSa
Dana-Farber @danafarber
“We’re changing the way people are cared for, through #precisionmedicine, precision care, and a total team approach… https://t.co/RnZXsH2rW8
Dana-Farber @danafarber
Cell-weighing method could help doctors choose #cancer drugs: https://t.co/YesjtyxIvR via @MIT https://t.co/0F7wsZSuLJ

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.